CN111603566A - A kind of presentation carrier complex targeting respiratory mucosa and its application - Google Patents

Abstract

The present invention provides a presentation carrier complex targeting animal respiratory mucosa and its application. The presentation carrier complex is prepared by mixing an appropriate amount of presentation carrier deacetylated chitosan and an appropriate amount of adjuvant tetanus toxoid. The presentation carrier complex can be used together with an immunogen to produce a vaccine to prevent the corresponding animal disease. The invention solves the problem that the immune complex vaccine targeting the respiratory mucosa of animals lacks an effective presentation carrier, improves the presentation efficiency of the immune products targeting the respiratory mucosa of animals, and enhances the immune response of the respiratory mucosa. The application of the inventive technology can effectively protect the health of animals, resist animal diseases mainly infected through the respiratory mucosa, and improve the economic benefits of the breeding industry.

Description

A kind of presentation carrier complex targeting respiratory mucosa and its application

technical field

The invention relates to the technical field of animal biological preparations, in particular to a preparation method of a presentation carrier complex targeting the respiratory mucosal system of animals, in particular to a presentation carrier complex targeting respiratory mucosal immunity and its application.

Background technique

At present, there are live vaccines for the immune products against pathogenic microorganisms mainly infected by the respiratory tract of animals, such as vaccines to prevent mycoplasma infection in poultry, pigs, cattle and other animals, new city vaccines for poultry, infectious bronchitis vaccines, etc. Mucosal immunity induces mucosal immunity and systemic immune responses in animals, thereby protecting animals from infection by corresponding foreign pathogens. However, some pathogenic microorganisms that affect animal health, such as influenza virus, foot-and-mouth disease virus and other inactive attenuated vaccines, make the prevention and control of pathogens infected through the respiratory tract such as influenza virus lack of mucosal immune barrier - lack of mucosal resistance. The result in production practice is that although inactivated vaccines have been used to prevent animals and induce humoral immunity in animals, the first mucosal barrier of animals is open, and pathogens can still be infected and multiply in the upper respiratory tract mucosa of animals. , can not be removed in time, and the animals can still develop influenza under stress conditions, thus causing serious economic losses to the breeders. This indicates that there is a need for biological or immune products targeting pathogenic microorganisms that prevent respiratory mucosal infections.

Second, some technologies targeting mucosal vectors are already common. Some chemical molecules such as liposomes, chitosan, alginate and other carriers, as well as some biological parts such as bacteria secreted: cholera toxin, E. coli toxin, tetanus toxoid, etc., can be used as adjuvants in vaccines. It can overcome the limitation of extracellular barriers, protect immunogens from being degraded by extracellular nucleases, play an adjuvant role, promote the recruitment and activation of immune cells in animals, and improve the immune response level of the body. Some of these substances, such as liposomes and chitosan, are presentation carriers, which play a role in presentation and transport to a certain extent, and further enhance the mucosal immunity of animals. There are also techniques or reports about its use in some biological products. There are also some microorganisms that can be used as carriers after being modified, such as Salmonella, lactic acid bacteria, adenovirus, etc. Some of these carriers and adjuvants have been used in actual production, but it is urgent to use a presentation carrier compound adjuvant carrier, and then combine with an immunogen (such as influenza virus) to make a vaccine or immune complex technology for animal mucosal immunity . In other words, the production lacks the corresponding presentation carrier and adjuvant complex targeting mucosal immunity.

The technology of the present invention is aimed at this, using (non-toxic to animals, can effectively contact with animal mucosa, so that the exogenous substances carried by it fully contact with the cells on the surface of animal mucosa, and induce an effective immune response) to present the carrier chitosan The carbohydrate complex adjuvant tetanus toxoid (with good adjuvant properties) forms an adjuvant presentation carrier complex to make up for the lack of preparation technology for products targeting animal respiratory mucosal immunity in production.

The technology of the present invention can be effectively combined with immunogens (such as screened and inactivated H9N2 influenza virus) to form an immune complex vaccine targeting mucosa. The vaccine can be used in animals by nasal drip or even spray to improve the mucosal resistance of animals, and can effectively prevent animal diseases that are infected through the respiratory mucosa, reduce the incidence of these diseases, protect animal health, and increase economic benefits.

SUMMARY OF THE INVENTION

The object of the present invention is to provide a kind of presenting carrier complex by targeting animal respiratory mucosal immunity, in order to solve the problem that there is no good complex for animal mucosal immunity in the prior art, so as to develop targeted respiratory mucosal immunity Provide technical support for vaccine delivery vehicles. This will effectively protect animal health and improve the economic benefits of the breeding industry.

The present invention provides a presentation carrier complex targeting respiratory mucosa, including the selected adjuvant and presentation carrier ratio;

The presentation carrier complex is prepared by dissolving an appropriate amount of presentation carrier deacetylated chitosan and an appropriate amount of adjuvant tetanus toxoid in a phosphate buffer, and mixing them in a certain proportion during use.

The presentation carrier complex can be produced in complex with an immunogen to prevent corresponding animal diseases. When in use, a certain quality of adjuvant tetanus toxoid, a certain quality of presentation carrier chitosan, a certain amount of the immunogen, mixed evenly, and added with a freeze-drying protective agent and a preservative to prepare the target. The carrier immune complex vaccine is delivered to the respiratory mucosa of animals, and it can be used.

Detailed ways

A complete description will be given below in conjunction with the technical solutions of the present invention.

Preparation of the carrier complex of the present invention. An appropriate amount of the presentation carrier chitosan was weighed with an analytical balance and dissolved in a phosphate buffer, while an appropriate amount of adjuvant tetanus toxoid was dissolved in a phosphate buffer, and the two solutions were used for later use.

Immune complex-vaccine preparation. According to a certain proportion of the vaccine, take a certain amount of adjuvant tetanus toxoid, a certain amount of presentation carrier chitosan, a certain amount of immunogen, mix well, add a certain amount of freeze-drying protective agent, Then an appropriate amount of preservative thimerosal is added for freeze-drying storage, which becomes a presentation carrier immune complex vaccine targeting respiratory mucosa. The vaccine can prevent the corresponding diseases by immunizing animals by nasal drip or spray.

In general, the presenting carrier complex targeting the respiratory mucosa of animals provided by the present invention can be used as an immune adjuvant carrier after the complex is formed by an adjuvant and a presentation carrier for the production or development of a vaccine targeting the respiratory mucosa. product. The product can induce mucosal antibodies by targeting the mucosal system of livestock and poultry, and play a good role in mucosal barrier immunity, thereby resisting animal diseases such as influenza and mycoplasma infection mainly through respiratory mucosal infections, protecting animal health and improving breeding. benefit. In addition, it makes up for the deficiencies of the current major immune products.

Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution, not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand: it can still be Modifications are made to the technical solutions described in the foregoing embodiments, or some or all of the technical features thereof are equivalently replaced; and these modifications or replacements do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.

Claims (3)

1. A presentation carrier compound targeting animal respiratory mucosa and its application are provided. It is characterized by an adjuvant presentation carrier compound targeting the respiratory tract mucosa immunity of animals.

2. The composition of the delivery carrier compound for targeting the respiratory mucosa of animals according to claim 1, the ratio of the components of the delivery carrier compound, the adjuvant and the delivery carrier and the preparation method thereof. The presenting carrier compound targets an animal respiratory tract mucous membrane system, can promote immunogen to fully contact mucous membrane cells, effectively stimulates animal mucous membrane immune reaction, and plays a role in portal immunity.

3. The animal respiratory mucosa targeting presentation vector complex and the use thereof according to claim 1, wherein the animal respiratory mucosa targeting presentation vector complex prepared by the method is used in production.